Clinical Takeaway
Across randomized clinical trials, cannabis derivatives and their analogs showed promising early signals for improving core and associated symptoms of autism spectrum disorder, including social communication and behavioral challenges. The evidence base remains limited in size and scope, and no firm conclusions about efficacy or optimal dosing can yet be drawn.
#13 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
Citation: Riera Rachel et al.. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.. Journal of clinical pharmacology. 2025. PMID: 40605143.
Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0
This systematic review addresses a significant gap in evidence for treating core autism spectrum disorder symptoms and associated behavioral dysregulation, where current pharmacological options remain limited and often inadequately effective. By synthesizing randomized clinical trial data on cannabis derivatives and analogs, the study provides clinicians with a rigorous assessment of efficacy and safety profiles to inform treatment decisions for patients with autism who have not responded to conventional interventions. The findings could establish a foundation for targeted cannabinoid-based therapies as an evidence-supported option within the autism treatment landscape.
Abstract: Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
? While emerging evidence suggests cannabis derivatives, particularly CBD-rich formulations, may help reduce irritability, anxiety, and challenging behaviors in some autistic individuals, the current literature remains limited by small sample sizes, heterogeneous outcome measures, and inconsistent dosing protocols that make firm clinical recommendations premature. The neurobiological mechanisms underlying any therapeutic effect in autism are not well established, and we lack adequate long-term safety data, particularly regarding neurodevelopmental impacts in younger patients and potential drug interactions with commonly prescribed psychiatric medications. Additionally, many studies conflate cannabinoid type and ratio, making it difficult to determine which specific formulations might be most beneficial for particular symptom clusters within the autism spectrum. Given these limitations, clinicians considering cannabis derivatives for autistic patients should do so within a shared decision-making framework that includes thorough baseline and monitoring assessments, careful documentation of which specific symptoms are targeted, and realistic expectations about effect sizes while awaiting higher-quality evidence. Practitioners should particularly emphasize that cannabis is not a replacement for established behavioral and
| |
Have thoughts on this? Share it:
